The pathogenesis of tuberculosis
- PMID: 8905081
- DOI: 10.1146/annurev.micro.50.1.259
The pathogenesis of tuberculosis
Abstract
Tuberculosis patients relapse if treatment is not continued for 6 months, because chemotherapy fails to convert the patients' response from the necrotizing pattern characteristic of disease (Koch phenomenon) to the nonnecrotizing bactericidal function required for optimal immunity. We need to understand the nature of these two immunological states and how to convert one to the other. Studies in mice and humans implicate differences in cytokine profiles and in metabolism of adrenal steroids. Either enhanced susceptibility or protection can be evoked in mice with appropriate doses of a killed environmental saprophyte. This emphasizes the importance of shared epitopes and may explain the geographically variable efficacy of Mycobacterium bovis Bacillus Calmette Guérin vaccination. Unlike soluble antigens of M. tuberculosis itself, which tend to evoke necrosis, the shared mycobacterial epitopes evoke little skin-test reactivity in patients. Preparations of these epitopes show potential as immunotherapeutic agents to convert the response from necrotic to bactericidal mode.
Similar articles
-
Loss of anti-mycobacterial efficacy in mice over time following vaccination with Mycobacterium bovis bacillus Calmette-Guérin.Vaccine. 2011 Sep 16;29(40):6881-7. doi: 10.1016/j.vaccine.2011.07.051. Epub 2011 Jul 29. Vaccine. 2011. PMID: 21803102
-
A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis.Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):115-26. doi: 10.1016/j.tube.2004.10.004. Epub 2005 Jan 22. Tuberculosis (Edinb). 2005. PMID: 15687035
-
Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.Vaccine. 2008 Feb 13;26(7):924-32. doi: 10.1016/j.vaccine.2007.12.005. Epub 2007 Dec 26. Vaccine. 2008. PMID: 18192091
-
Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention.Novartis Found Symp. 1998;217:73-87; discussion 87-98. doi: 10.1002/0470846526.ch6. Novartis Found Symp. 1998. PMID: 9949802 Review.
-
[Evolution of IGRA researches].Kekkaku. 2008 Sep;83(9):641-52. Kekkaku. 2008. PMID: 18979999 Review. Japanese.
Cited by
-
Characterisation and development of histopathological lesions in a guinea pig model of Mycobacterium tuberculosis infection.Front Vet Sci. 2023 Sep 22;10:1264200. doi: 10.3389/fvets.2023.1264200. eCollection 2023. Front Vet Sci. 2023. PMID: 37808110 Free PMC article.
-
Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.Hum Vaccin Immunother. 2014;10(5):1238-43. doi: 10.4161/hv.28249. Epub 2014 Mar 7. Hum Vaccin Immunother. 2014. PMID: 24607935 Free PMC article.
-
Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection.J Clin Microbiol. 2004 Aug;42(8):3469-74. doi: 10.1128/JCM.42.8.3469-3474.2004. J Clin Microbiol. 2004. PMID: 15297485 Free PMC article.
-
Functional analysis of the Mycobacterium tuberculosis MprAB two-component signal transduction system.Infect Immun. 2003 Dec;71(12):6962-70. doi: 10.1128/IAI.71.12.6962-6970.2003. Infect Immun. 2003. PMID: 14638785 Free PMC article.
-
Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment.BMC Complement Altern Med. 2013 Oct 7;13:258. doi: 10.1186/1472-6882-13-258. BMC Complement Altern Med. 2013. PMID: 24098949 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources